Sun Pharma gains on higher prices for drugs
Reuters Market Eye - Shares in Sun Pharmaceutical Industries(SUN.NS) gain 1.8 percent after Credit Suisse said the drug maker's subsidiary Taro Pharmaceutical Industries (TARO.N) has pushed through price increases in three products last week, citing industry checks.
Credit Suisse estimates those three drugs account for 35 percent of Taro U.S. sales.
The price increases raise sustainable sales estimates for Taro to $680 million versus $640 million earlier for FY 2015, the investment bank adds.
Credit Suisse maintains its "outperform" rating on the stock and raises its target price to 900 rupees from 840 rupees, in part by factoring higher sales estimates for Taro.
(Reporting by Abhishek Vishnoi)
- Tweet this
- Share this
- Digg this
- Storm to cloak Midwest to Northeast in snow, freezing rain
- Insight - In Yemen, al Qaeda gains sympathy amid U.S. drone strikes
- UPDATE 1-Would-be millionaires rush into 2nd-largest U.S. Mega Millions drawing
- UPDATE 2-Canada household debt-to-income ratio hits record high
- Insight: In Yemen, al Qaeda gains sympathy amid U.S. drone strikes
The Sensex fell on Friday to mark its biggest weekly fall in nearly a month, as rate-sensitive stocks such as ICICI Bank fell on caution ahead of the RBI's policy review and the U.S. Federal Reserve meet next week. Article
Asia-Pacific M&A volume falls for third consecutive year, deal size grows. Full Article